Author(s): Ranjini D.M, Sadiq Basha G, Prabakaran N.

Email(s): ranjinidm56@gmail.com , gsadiqbasha@gmail.com

DOI: 10.52711/0974-360X.2021.00600   

Address: Ranjini D.M*, Sadiq Basha G, Prabakaran N.
1Regulatory Executive in Generic Formulation Regulatory Science, Biocon Pharma Limited, 20th KM, Hosur Road, Electronic City, Bengaluru, Karnataka 5600100.
2Associate Vice President – Regulatory Science Biocon Pharma Limited, 20th KM, Hosur Road, Electronic City, Bengaluru, Karnataka 5600100.
3Manager in Regulatory Sciences – Generic Formulations Biocon Pharma Limited, 20th KM, Hosur Road, Electronic City, Bengaluru, Karnataka 5600100.
*Corresponding Author

Published In:   Volume - 14,      Issue - 6,     Year - 2021


ABSTRACT:
Objectives of the present work are as follows: • To study the current principles of rare diseases & orphan drugs. • To study the assessment, challenges and regulatory frame work of orphan drugs • To study the integrated approach for the development and approval of orphan drugs. • To carry out the study of globalization in orphan drug development strategies in US & EU markets. Methods: Internet using web page content: The literature was collected using numerous search engines e.g. Science Direct, Google Scholar and many more. Online books also served as a good source of information. Documents and information’s collected using numerous regulatory websites such as: a) USFDA: https://www.fda.gov b) EMA: https://www.ema.europa.eu/en c) CANADA: https://www.canada.ca/en/health-canada.html d) TGA: https://www.tga.gov.au/ e) INDIA: http://www.cdsco.com/ Results: US- FDA Approved Orphan Drug ex: Tafenoquine - Treatment of malaria - Krintafel is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria. EU – EMA Approved Orphan Drug ex: Eculizumab, Soliris - Treatment myasthenia gravis. Conclusion: The orphan drug guidelines made via distinct countries have established as promoters in development of orphan drugs. The orphan drug regulation in the US and the EU has been a success in offering remedies to the patients with rare diseases.


Cite this article:
Ranjini D.M, Sadiq Basha G, Prabakaran N. Regulatory Strategies for Orphan drug Development in USA–Europe. Research Journal of Pharmacy and Technology. 2021; 14(6):3449-4. doi: 10.52711/0974-360X.2021.00600

Cite(Electronic):
Ranjini D.M, Sadiq Basha G, Prabakaran N. Regulatory Strategies for Orphan drug Development in USA–Europe. Research Journal of Pharmacy and Technology. 2021; 14(6):3449-4. doi: 10.52711/0974-360X.2021.00600   Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-6-90


REFERENCES:
1.    Singh MK, Sharma PK, Sharma N. Orphan Drug Development: A Brief Review. Journal of Pharmacy Research. 2011; 4(8):2645–7. 2.
2.    European Medicine Agency [Internet]. Medicines for Rare Diseases: 3–5; 2016 [cited 2016 Apr 13]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ special topics/general/general_content_000034.jsp.
3.     Engel PA, Bagal S, Broback M, Boice N. The Need for Stronger Educational Initiatives for Physicians. Journal of Rare Disorder. 2013; 1(2):1–15.
4.     Hall AK and Carlson MR. the Current Status of Orphan Drug Development in Europe and the US. International Journal of Rare Disorder Research. 2014; 3(1): 1–7.
5.     Orphan Drug Report [Internet]. Welcome to the Evaluate Pharma Orphan Drug Report. [updated 2015 oct 30; cited 2016 Apr 3] Available from: http://www.evaluategroup.Com/public/reports/Evalua tePharma-Orphan-Drug-Report-2015.
6.    Jyothi G, Venkatesh M, Kumar PT, Radhadevi N, Gundavaram R and Sharma KK: Orphan Drug Act: History, Perspective and Challenges for Future. Am J PharmTech Res 2012; 2249-3387.
7.     Schieppati A, Henter JI, Daina E and Aperia A: Why rare diseases are an important medical and social issue. The Lancet 2008; 371(9629): 2039-41.
8.     Haffner ME: Adopting orphan drugs-two dozen years of treating rare diseases. New England Journal of Medicine 2006; 354(5): 445-7.
9.     Stakisaitis D, Spokiene I, Juskevicius J, Valuckas KP and Baiardi P: Access to information supporting the availability of medicines for patients suffering from rare diseases looking for possible treatments: the European Service. Medicine (Kaunas, Lithuania) 2007; 43(6): 441-6.
10.     Wästfelt M, Fadeel B and Henter JI: A journey of hope: lessons learned from studies on rare diseases and orphan drugs. Journal of Internal Medicine 2006; 260(1): 1-10.
11.    FDA. Available from: http://www.fda.gov/downloads/ For Consumers.

Recomonded Articles:

Author(s): Satheesh S, S Abimanyu, R. Kamaraj

DOI: 10.5958/0974-360X.2020.00275.9         Access: Open Access Read More

Author(s): Ranjini D.M, Sadiq Basha G, Prabakaran N.

DOI: 10.52711/0974-360X.2021.00600         Access: Closed Access Read More

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags